Chronic gastritis Medical Services in China

Chronic gastritis is a persistent, long-term inflammatory condition of the gastric mucosa, characterized by histological evidence of chronic inflammatory cell infiltration—primarily lymphocytes and plasma cells—often accompanied by glandular atrophy, intestinal metaplasia, or dysplasia in advanced cases. Unlike acute gastritis, which presents with sudden, transient symptoms, chronic gastritis develops insidiously over months to years and may remain asymptomatic for extended periods. Its pathogenesis is multifactorial: Helicobacter pylori infection accounts for approximately 80–90% of cases globally and triggers sustained immune-mediated mucosal injury through virulence factors (e.g., CagA, VacA) and host genetic susceptibility. Other key mechanisms include autoimmune gastritis (targeting parietal cells and intrinsic factor, leading to pernicious anemia), long-term use of NSAIDs or aspirin (disrupting prostaglandin-mediated mucosal defense), bile reflux, chronic alcohol consumption, smoking, and systemic conditions such as Crohn’s disease or sarcoidosis. Epidemiologically, chronic gastritis affects an estimated 50% of the global adult population, with prevalence rising sharply with age—reaching 70–80% in individuals over 60 years. H. pylori seroprevalence remains particularly high in low- and middle-income countries (>70%), while autoimmune and NSAID-related subtypes predominate in Western aging populations. Major modifiable risk factors include untreated H. pylori infection, habitual NSAID use, smoking, excessive alcohol intake, poor dietary habits (e.g., high-salt, smoked, or nitrate-rich foods), and chronic psychological stress. Non-modifiable risks include older age, female sex (for autoimmune gastritis), and genetic polymorphisms in IL-1β and TNF-α genes. Although many patients are asymptomatic, symptomatic individuals commonly report nonspecific upper gastrointestinal complaints—including postprandial epigastric discomfort, early satiety, nausea, bloating, and occasional anorexia. Importantly, chronic gastritis significantly impacts quality of life: longitudinal studies show reduced physical functioning, increased anxiety and depression scores, impaired work productivity, and diminished social engagement—particularly among those with persistent symptoms or complications like iron-deficiency anemia or vitamin B12 deficiency. In a subset of patients, especially those with atrophic gastritis and intestinal metaplasia, there is an elevated risk of gastric adenocarcinoma (up to 6-fold higher over 10–20 years), underscoring the importance of endoscopic surveillance in high-risk groups. Early diagnosis via upper endoscopy with targeted biopsies—and accurate histopathological classification using the Updated Sydney System—is essential for risk stratification and personalized management.

Chronic gastritis is a persistent inflammatory condition of the gastric mucosa, characterized histologically by infiltration of mononuclear inflammatory cells (lymphocytes and plasma cells), glandular atrophy, intestinal metaplasia, and/or fibrosis. It is not a single disease but a heterogeneous group of disorders with diverse etiologies, natural histories, and clinical implications. The most prevalent and well-established cause worldwide is chronic infection with Helicobacter pylori, a gram-negative, microaerophilic bacterium that colonizes the gastric mucus layer and adheres to surface epithelial cells. H. pylori induces a robust immune response, leading to sustained mucosal inflammation, oxidative stress, and progressive architectural changes—including loss of parietal and chief cells—over decades. Eradication of H. pylori significantly reduces inflammation and halts progression in most cases, underscoring its central pathogenic role.

Autoimmune gastritis represents a distinct etiologic subtype, accounting for approximately 5–10% of chronic gastritis cases, particularly in individuals of Northern European descent. It results from T-cell–mediated destruction of gastric parietal cells and intrinsic factor–producing cells, driven by autoantibodies against the H+/K+ ATPase proton pump and intrinsic factor. This leads to achlorhydria, hypergastrinemia, pernicious anemia, and increased risk of gastric neuroendocrine tumors and adenocarcinoma. Genetic susceptibility plays a key role: polymorphisms in HLA class II genes (especially HLA-DQA1*05:01 and HLA-DRB1*03:01) confer heightened risk, and first-degree relatives exhibit elevated prevalence, suggesting polygenic inheritance patterns.

Environmental and behavioral risk factors substantially modulate disease onset and progression. Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin disrupts gastric mucosal defense via cyclooxygenase-1 (COX-1) inhibition, reducing prostaglandin synthesis critical for mucus/bicarbonate secretion, mucosal blood flow, and epithelial repair. Chronic alcohol consumption (>40 g/day) induces direct cytotoxicity, impairs mucosal barrier function, and promotes oxidative injury. Smoking exacerbates inflammation, delays ulcer healing, and increases risk of atrophic gastritis and gastric cancer through nicotine-mediated vasoconstriction and carcinogen-induced DNA damage.

Dietary factors contribute meaningfully: diets high in salted, smoked, or nitrate-preserved foods promote N-nitroso compound formation and epithelial injury; low intake of antioxidants (vitamins C, E, selenium) and fresh fruits/vegetables diminish mucosal defense against oxidative stress. Chronic bile reflux—often following gastrectomy, cholecystectomy, or due to pyloric sphincter dysfunction—introduces cytotoxic bile acids (e.g., deoxycholic acid) into the stomach, causing chemical injury and promoting inflammation and metaplasia.

Other infectious agents, though less common, include cytomegalovirus (CMV) in immunocompromised hosts (e.g., HIV/AIDS, post-transplant), Epstein-Barr virus (EBV) in lymphoproliferative disorders, and rarely, Mycobacterium avium complex or syphilis. Systemic conditions such as Crohn’s disease, sarcoidosis, eosinophilic gastroenteritis, and collagen vascular diseases (e.g., systemic lupus erythematosus, vasculitides) may involve gastric mucosa secondarily. Chronic renal failure, liver cirrhosis, and severe burns (Curling ulcers) are associated with stress-related mucosal damage that may evolve into chronic changes if unresolved.

Psychosocial stress does not directly cause chronic gastritis but may amplify symptom perception (functional dyspepsia overlap) and impair mucosal recovery via autonomic dysregulation and altered gut-brain axis signaling. Occupational exposures—such as prolonged exposure to dust, solvents, or heavy metals—remain under-investigated but plausible contributors in specific cohorts. Age is a non-modifiable risk factor: prevalence of atrophic gastritis and intestinal metaplasia rises markedly after age 50, reflecting cumulative mucosal insult and declining regenerative capacity. Finally, socioeconomic determinants—including childhood overcrowding, poor sanitation, and limited access to clean water—strongly correlate with early-life H. pylori acquisition and subsequent chronic gastritis burden, highlighting the profound influence of environmental context on disease epidemiology and natural history.

Chronic gastritis is a persistent, low-grade inflammatory condition of the gastric mucosa, typically developing over months to years. It is commonly encountered in gastroenterology practice and may result from multiple etiologies—including Helicobacter pylori infection (the most prevalent cause worldwide), long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), autoimmune mechanisms (autoimmune atrophic gastritis), bile reflux, chronic alcohol consumption, smoking, or systemic disorders such as Crohn’s disease or sarcoidosis. Unlike acute gastritis, which presents with abrupt, often severe symptoms, chronic gastritis frequently exhibits subtle, nonspecific, or even asymptomatic clinical manifestations—particularly in its early stages—making it challenging to recognize without targeted evaluation.

Early symptoms are often mild, intermittent, and easily attributed to functional dyspepsia or dietary indiscretion. Patients may report vague epigastric discomfort or a sensation of fullness after meals (early satiety), mild nausea without vomiting, or occasional belching. Some describe a dull, burning, or gnawing epigastric ache that worsens with fasting and improves transiently with food intake—though this pattern is less consistent than in peptic ulcer disease. Mild anorexia or reduced appetite may be noted, especially in elderly patients. Importantly, up to 70% of individuals with histologically confirmed chronic gastritis remain entirely asymptomatic during the initial phase, underscoring the importance of endoscopic surveillance in high-risk populations (e.g., those with family history of gastric cancer, pernicious anemia, or longstanding H. pylori infection).

Typical symptoms—when present—reflect ongoing mucosal irritation and impaired gastric physiology. Persistent or recurrent epigastric pain or discomfort remains the most common complaint, though its character is usually less intense and more diffuse than in acute erosive gastritis. Dyspepsia dominates the clinical picture: including postprandial bloating, upper abdominal pressure, and subjective heaviness. Nausea occurs more frequently than vomiting; when emesis does occur, it is typically non-bilious and non-projectile, and rarely associated with hematemesis unless erosions or ulcers coexist. Some patients experience acid regurgitation or water brash, particularly in cases with concomitant gastroesophageal reflux disease (GERD) or bile reflux gastritis. In autoimmune atrophic gastritis, symptoms may be delayed for decades but eventually reflect progressive gastric atrophy and hypochlorhydria—manifesting as iron-deficiency anemia (due to impaired non-heme iron absorption), megaloblastic anemia (from vitamin B12 malabsorption secondary to intrinsic factor deficiency), glossitis, or mild peripheral neuropathy.

Accompanying symptoms often reflect comorbidities or downstream consequences of chronic inflammation. Fatigue and pallor may signal underlying anemia. Unintentional weight loss—though not universal—warrants urgent investigation, as it raises concern for malignancy or advanced atrophy. Patients with H. pylori–associated gastritis may exhibit halitosis or recurrent oral aphthae. Those with bile reflux may report a bitter taste, especially upon waking or after reclining. In older adults, cognitive complaints (e.g., mild confusion or memory lapses) may emerge secondary to chronic B12 deficiency. Gastrointestinal motility disturbances—including delayed gastric emptying—can contribute to prolonged postprandial fullness and erratic blood glucose fluctuations in diabetic patients.

Complications arise primarily from sustained mucosal injury and architectural remodeling. Atrophic gastritis predisposes to intestinal metaplasia—a precancerous change wherein gastric epithelium is replaced by intestinal-type columnar cells—increasing lifetime risk of gastric adenocarcinoma (particularly the intestinal type). Dysplasia may evolve within metaplastic fields, representing a direct precursor lesion. Autoimmune gastritis carries elevated risk of gastric neuroendocrine tumors (type I carcinoids), arising from hypergastrinemia-induced enterochromaffin-like (ECL) cell hyperplasia. Iron deficiency anemia results from chronic mucosal bleeding, impaired iron absorption in hypochlorhydric environments, or both. Vitamin B12 deficiency leads to subacute combined degeneration of the spinal cord if untreated. Rarely, severe atrophy culminates in gastric achlorhydria, increasing susceptibility to bacterial overgrowth (e.g., enteric pathogens or nitrate-reducing bacteria), which may further promote carcinogenesis via nitrosamine formation.

Diagnosis relies on a multimodal approach. Upper gastrointestinal endoscopy (esophagogastroduodenoscopy, EGD) is the gold standard, enabling direct visualization of mucosal changes—including erythema, edema, mucosal friability, erosions, hemorrhagic spots, or atrophic pallor—and facilitating targeted biopsies. Histopathological examination of biopsy specimens (preferably from antrum, corpus, and incisura angularis) confirms chronic inflammation (lymphocytes and plasma cells), assesses glandular atrophy, intestinal metaplasia, and activity (neutrophil infiltration). Special stains (e.g., Giemsa, immunohistochemistry) detect H. pylori. Serologic testing for anti-parietal cell and anti-intrinsic factor antibodies supports diagnosis of autoimmune gastritis. Noninvasive tests include urea breath test, stool antigen assay, and serum H. pylori IgG—though serology cannot distinguish active from past infection. Serum pepsinogen I/II ratio and gastrin-17 levels serve as biomarkers of gastric atrophy and acid secretion status, particularly useful in population screening. Complete blood count, serum ferritin, vitamin B12, and methylmalonic acid help evaluate nutritional sequelae.

Differential diagnosis must exclude conditions mimicking chronic gastritis clinically or endoscopically. Functional dyspepsia shares overlapping symptoms but lacks objective mucosal abnormalities on endoscopy or histology. Peptic ulcer disease typically demonstrates discrete mucosal breaks on endoscopy and may present with more localized, meal-related pain patterns. Gastric malignancy (adenocarcinoma or lymphoma) may present with similar nonspecific symptoms but reveals mass lesions, ulcerations with irregular margins, or nodularity on EGD; biopsy is mandatory to rule out neoplasia. Eosinophilic gastritis features prominent eosinophilic infiltration on biopsy and often correlates with peripheral eosinophilia or allergic comorbidities. Lymphocytic gastritis shows intraepithelial lymphocytosis (>25 lymphocytes per 100 epithelial cells) and is frequently associated with celiac disease. Crohn’s gastritis may show linear ulcers or cobblestoning, often with concurrent ileocolonic involvement. Medication-induced injury (e.g., NSAIDs, bisphosphonates, potassium chloride) requires careful drug history review. Finally, systemic diseases—including amyloidosis, vasculitides (e.g., granulomatosis with polyangiitis), or infectious causes (e.g., cytomegalovirus in immunocompromised hosts)—must be considered in atypical presentations or treatment-refractory cases.

Chronic gastritis is a persistent inflammatory condition of the gastric mucosa, often resulting from long-standing Helicobacter pylori infection, autoimmune mechanisms, bile reflux, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), or chronic alcohol consumption. Its clinical presentation varies widely—from asymptomatic endoscopic findings to nonspecific symptoms such as epigastric discomfort, early satiety, postprandial bloating, nausea, and occasionally iron-deficiency anemia or vitamin B12 deficiency in atrophic or autoimmune subtypes. Accurate diagnosis relies on upper gastrointestinal endoscopy with targeted biopsies for histopathological assessment, H. pylori testing (via rapid urease test, histology, stool antigen assay, or urea breath test), and serologic evaluation when autoimmune gastritis is suspected.

Conservative treatment forms the cornerstone of management and emphasizes lifestyle and dietary modification alongside risk factor mitigation. Patients are advised to avoid known gastric irritants—including NSAIDs, aspirin, corticosteroids, alcohol, tobacco, and highly spiced, acidic, or fried foods. Eating smaller, more frequent meals helps reduce gastric distension and acid exposure. Stress reduction techniques—such as cognitive behavioral therapy, mindfulness-based stress reduction, or regular physical activity—are recommended given the bidirectional relationship between psychological stress and gastric motility/acid secretion. Weight optimization is encouraged in patients with gastroesophageal reflux–associated gastritis, and elevation of the head of the bed may be beneficial in those with nocturnal symptoms suggestive of bile or acid reflux. Importantly, conservative measures must be individualized: for instance, patients with autoimmune gastritis require lifelong monitoring for pernicious anemia and osteoporosis but do not benefit from acid suppression alone; whereas those with reflux gastritis may respond well to positional and dietary adjustments.

Pharmacotherapy is tailored to etiology and symptom burden. First-line treatment for H. pylori–positive chronic gastritis is eradication therapy, typically a 14-day bismuth quadruple regimen (proton pump inhibitor [PPI] twice daily, bismuth subsalicylate, tetracycline, and metronidazole) or a high-dose dual therapy (PPI four times daily plus amoxicillin). Clarithromycin-based triple therapy is no longer recommended in most regions due to widespread resistance (>20% in China). For symptomatic relief in H. pylori–negative cases, PPIs (e.g., esomeprazole 20–40 mg once daily) remain first-line for reducing acid-mediated mucosal injury and promoting healing. Histamine-2 receptor antagonists (e.g., famotidine) offer milder acid suppression and may be used for intermittent or mild symptoms. Sucralfate—a cytoprotective agent—forms a viscous barrier over erosions and enhances mucosal defense, particularly useful in NSAID-induced or bile-reflux gastritis. In autoimmune gastritis, replacement therapy is essential: intramuscular or high-dose oral vitamin B12 (1000 µg weekly initially, then monthly maintenance) corrects deficiency and prevents irreversible neurologic sequelae; iron supplementation (oral ferrous sulfate or intravenous ferric carboxymaltose) addresses concomitant iron deficiency. Prokinetic agents (e.g., domperidone or low-dose erythromycin) may be considered in patients with documented gastroparesis contributing to symptoms.

Surgical intervention is exceedingly rare in chronic gastritis and reserved only for complications unresponsive to medical therapy. Indications include refractory bleeding from severe atrophic or erosive gastritis (requiring endoscopic hemostasis failure), gastric outlet obstruction secondary to fibrotic stricture (managed via endoscopic balloon dilation or, rarely, antrectomy), or suspicion of dysplasia or early gastric cancer on surveillance biopsies—prompting definitive resection (endoscopic submucosal dissection or laparoscopic gastrectomy). Surgery is never indicated for gastritis itself but rather for its neoplastic or structural sequelae. Preoperative evaluation mandates high-definition endoscopy with chromoendoscopy and multiple random biopsies to rule out malignancy.

Treatment in China offers distinct advantages rooted in integrated clinical infrastructure, epidemiologic expertise, and innovation. Chinese tertiary hospitals—especially those affiliated with academic centers like Peking Union Medical College Hospital or Zhongshan Hospital—maintain robust H. pylori antimicrobial resistance surveillance networks, enabling real-time, region-specific antibiotic selection. Endoscopic capabilities are world-class: narrow-band imaging (NBI), linked-color imaging (LCI), and artificial intelligence–assisted detection systems significantly improve early identification of atrophy, intestinal metaplasia, and dysplasia during routine surveillance. Moreover, China’s national gastric cancer screening program (initiated in high-risk regions such as Linzhou and Shandong) has generated unparalleled longitudinal data on gastritis progression, informing evidence-based follow-up intervals (e.g., 3-year surveillance for moderate atrophy vs. annual for extensive intestinal metaplasia). Traditional Chinese Medicine (TCM) is frequently integrated under rigorous protocols: formulas such as Weikangning decoction (containing Huang Qin, Bai Zhu, and Gan Cao) have demonstrated adjunctive efficacy in reducing inflammation and improving symptom scores in randomized controlled trials published in journals like *Gut* and *Clinical Gastroenterology and Hepatology*. Importantly, this integration occurs within allopathic frameworks—TCM is prescribed only after standard diagnostic workup and never as monotherapy for confirmed H. pylori or premalignant lesions.

Recovery and long-term management hinge on adherence, surveillance, and patient education. Patients should undergo repeat endoscopy with biopsy only if initial histology reveals atrophy, intestinal metaplasia, or dysplasia—otherwise, symptom resolution with therapy suffices. H. pylori eradication must be confirmed via urea breath test or stool antigen assay ≥4 weeks after therapy completion. Nutritional counseling is critical: patients with atrophic gastritis require regular serum pepsinogen I/II ratio, gastrin-17, and ferritin assessments; those with autoimmune disease need annual B12, methylmalonic acid, and complete blood count monitoring. Smoking cessation and strict NSAID avoidance are non-negotiable. Finally, psychosocial support—including access to gastroenterology-led patient education groups and digital health platforms offering symptom diaries and medication reminders—has been shown in Chinese cohort studies to improve 12-month treatment adherence by over 35%. With comprehensive, etiology-driven care, most patients achieve durable symptom control and significantly reduced risk of progression to gastric adenocarcinoma.